Found 462 articles
Sosei Group Corporation provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2021.
Jennifer Doudna will act as Chief Science Advisor to build a Scientific Advisory Board for Sixth Street, advising the investment firm on CRISPR-related opportunities.
Pfizer Inc. (NYSE: PFE) reported strong financial results for fourth-quarter and full-year 2021 and provided 2022 total company financial guidance(4).
NURTEC® ODT When Taken as an Acute Treatment for Migraine Reduces Monthly Migraine Days: Expanded Data from Long Term Treatment Published in Cephalalgia Reports
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced the publication of new findings from its long-term safety study showing reductions in migraine frequency.
Sosei Group Corporation Proposes Changes to its Leadership Team as Part of Succession Plan to Drive the Company Through the Next Stage of its Evolution
Sosei Group Corporation, announces that its Board of Directors approved the nomination of candidates for its Representative Executive Officer, Directors and Executive Officers as stated below.
Elects Thomas Pfisterer and Douglas Manion, MD, FRCP(C), to the Board of Directors.
Global Coalition for Adaptive Research Announces Key Updates on GBM AGILE Phase 2-3 Adaptive Platform Trial for Patients With Glioblastoma
Global Coalition for Adaptive Research (GCAR) today announced an update on the progress of GBM AGILE (Glioblastoma Adaptive Global Innovative Learning Environment - NCT03970447).
Artizan Biosciences Selects Lead Product Candidate for Inflammatory Bowel Disease Therapeutic Development Program
Artizan Biosciences, Inc. today announced the selection of its lead product candidate, ARZC-001, for the treatment of inflammatory bowel disease (“IBD”).
Biohaven Enters Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain
Biohaven Therapeutics Ltd., a subsidiary of Biohaven Pharmaceutical Holding Company Ltd., along with CD3 and LICR at KU Leuven, announced that they have entered into an exclusive global license and research agreement to develop and commercialize first-in-class TRPM3 antagonists to address the growing proportion of people worldwide living with chronic pain disorders.
Sosei Heptares and Verily will collaborate to generate novel drug candidates against GPCR targets for immune-mediated diseases
Sosei Group Corporation and Verily, an Alphabet precision health company, announced they have entered into a strategic research collaboration.
Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE), today announced that the parties have completed the collaboration transaction between the two companies.
Sosei Group Corporation, announced its Chief Financial Officer, Chris Cargill, will present at the 40th Annual J.P. Morgan Healthcare Conference, which will take place virtually, on Monday, January 10, 2022.
Sosei Group Corporation announces that in connection with the Collaboration and License Agreement with Neurocrine Biosciences, Inc. announced 22 November 2021, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired on 22 December 2021.
Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies against GPCR Targets
Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in GPCR-focused structure-based drug design (SBDD) and development, and Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced a strategic collaboration to discover therapeutic antibodies against G protein-coupled receptors (GPCR) identified by Sosei Heptares.
12/13/2021There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
BIOHAVEN ANNOUNCES NURTEC® ODT RECEIVES FIRST GLOBAL APPROVAL OUTSIDE THE U.S. FOR PREVENTION OF MIGRAINE
Biohaven Pharmaceutical Holding Company Ltd. announced today that NURTEC ODT (rimegepant) 75 mg was approved by the Ministry of Health of Israel for the preventive treatment of episodic migraine in adults.
The company said the study demonstrated broad efficacy, showing statistically significant superiority to placebo over a total of 15 prespecified primary and secondary outcome measures.
Biohaven Names CEO Vlad Coric, MD, Chairman Of The Board Of Directors And Matthew Buten, Chief Financial Officer
Biohaven Pharmaceutical Holding Company Ltd. today announced that the Board of Directors unanimously elected Vlad Coric, MD to the role of Chairman of the Board of Directors following the retirement of Declan Doogan, MD, effective immediately.
Biohaven Reports Positive Topline Results from Pivotal Migraine Trial of Intranasal Zavegepant Demonstrating Ultra-Rapid Pain Relief by 15 minutes; Prepares for Submission of New Drug Application
Biohaven today announced positive topline results from the second pivotal clinical trial (NCT04571060) evaluating the safety and efficacy of its investigational therapy, intranasal zavegepant, for the acute treatment of migraine in adults.
Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders
Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878 in schizophrenia in 2022 and Phase 1 studies for a dual M1/M4 and selective M1 agonist in 2023.